Danaher soars to record quarter; Healthcare reform will benefit med tech, analysts say;

@FierceMedDev: Alere's proxy fight gets personal in latest round. More | Follow @FierceMedDev

 @MarkHFierce: The clock is ticking. Send in your 2013 FMD Fierce 15 nominations. Submit now | Follow @MarkHFierce

@DamianFierce: Quest dims revenue outlook as it sells stake in J&J cancer drug. Story | Follow @DamianFierce

> Danaher ($DHR) hauled in a record $4.7 billion in the second quarter, 4% over the same period last year, and net income rose 3.5% to $616.8 million. Results

> Despite all the hand-wringing over the 2.3% excise tax, RBC Capital Markets analysts say many medical device companies will benefit once the Affordable Care Act's insurance mandates kick in next year. Report

> TB Biosciences has raised a $1.5 million Series A to develop a point-of-care diagnostic for tuberculosis. Release

> Illumina ($ILMN) has launched a phasing analysis offering for its whole-genome mapping services, allowing researchers to identify segments of connected variants within a gene. News

> In an interview with The Los Angeles Times, Ambry Genetics CEO Charles Dunlop said Myriad Genetics' ($MYGN) lawsuit against his company is without merit. "I don't know what they're doing other than just bullying people," he said. Article

> India's FDA sealed the plant of a local device manufacturer after finding that some of its orthopedic implants weren't sterile. Story

> In a study published in the Journal of the American College of Cardiology, covered stents showed better patency at 12 months than standard bare-metal implants. Item

> Diagnostics outfit Venaxis ($APPY) has notched some positive early results for the APPY1 Test, designed to gauge a patient's risk of appendicitis, and the company said it's on track to file for FDA approval. More

Biotech News

@FierceBiotech: After Eylea win, Regeneron execs puzzle over R&D scale-up challenge. Article | Follow @FierceBiotech

 @JohnCFierce: Ensemble hasn't raised VC $$ since 2007--which is impressive. Funded by marquee collaborations. | Follow @JohnCFierce

 @EmilyMFierce: ICYMI: NIH confirms it's shelving India drug trials in wake of new regs. Editor's corner | Follow @EmilyMFierce

> Booming Alexion looks to Ensemble platform for ultrarare disease programs. Article

> OncoMed extends the biotech IPO winning streak with $82M haul. News

Pharma News

@FiercePharma: Merck taps India's Lupin to market pneumococcal vax under new name. In U.S., brand = Pneumovax 23. More | Follow @FiercePharma

 @CarlyHFierce: Vivus holding its annual meeting this morning. Stay tuned for the end of the proxy fight with First Manhattan--and its outcome. | Follow @CarlyHFierce

> Novartis under U.S. scrutiny for Gilenya marketing tactics. Story

> Deaths force Celgene to stop Revlimid CLL trial in its tracks. News

> Lilly freezes salaries ahead of patent loss for Cymbalta. Report

Pharma Manufacturing News

 @EricPFierce: From FierceVaccines.com: ABC's appointment of Jenny McCarthy sparks media furor. News | Follow @EricPFierce

> UAE expects big growth in generic drug production. Item

> Penn Pharma to expand plant opened in May. Report

> China regulators pledge new crackdown on counterfeit drug operations. More

> J&J says it has upped its quality game across all 120 plants. Article

> Cispharma warning letter says injury investigation inadequate. Story

Vaccines News

> Gates-backed device extends cold chain to rural areas. Report

> Bio Farma taps Artes for VLP technology. Item

> ABC's appointment of Jenny McCarthy sparks media furor. More

> New data supports vaccinating gay men against HPV. Story

> Sanofi starts up dengue vaccine plant to maintain edge over Takeda. Article

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.